Greg Fiore, MD

Gregory Fiore MD


Dr. Fiore is a pharmaceutical/biotechnology executive and entrepreneur and is the founder of Fiore Healthcare Advisors (FHA).  He is a co-founder, former CEO and the current Chief Medical Officer of  Sollis Therapeutics as well as the founder of SSI Strategy, a life science management consultancy.  He currently serves as advisor to FHA and SSI.

Dr. Fiore is a recognized expert in clinical research and pharmacovigilance (PV) and has particular passion for designing approaches to ensure the safety of subjects exposed to marketed drugs and to products in clinical trials.  He has overseen safety and clinical research for more than 10 therapy areas and has experience in the US, Europe, Asia Pacific, and Latin America.

Prior to founding FHA, Dr. Fiore was the Chief Medical Officer of The Medicines Company (MDCO) and had served in a variety of leadership roles at MDCO, Merck and Abbott Laboratories.

Dr. Fiore completed Internal Medicine internship and residency at Harvard Medical School’s Brigham and Women’s Hospital and received clinical training in Pulmonary & Critical Care Medicine at Harvard Medical School. From Harvard he joined McKinsey & Company where he worked on projects in a variety of industries including pharmaceuticals. He received his MD degree and was valedictorian at New York Medical College and received a bachelors degree in Zoology from the University of Rhode Island with honors.

Dr. Fiore serves on several Medical and Business Advisory Committees.  He is on the Executive Board of the Institute of Neuromodulation (ION), the Scientific Advisory Board for Advera Health Analytics, the Business Advisory Board for the Advanced Group of Companies, the Editorial Advisory Board of the journal Clinical Leader, and the Executive Committee for the Safety of Oral Anticoagulants (SOAR) Registry. He serves as the Lead Medical Advisor for Synspira, Inc. a privately held biotechnology company and has previously served on the Board of Dubset Media Holdings as well as participated on the CIOMS IX working group on Risk Minimization.